Analyst Price Targets — ARCT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 22, 2026 9:08 pm | — | Roth Capital | $20.00 | $7.59 | TheFly | Arcturus Therapeutics initiated with a Buy at Roth Capital |
| August 22, 2025 11:45 am | Lili Nsongo | Leerink Partners | $54.00 | $18.51 | TheFly | Arcturus Therapeutics price target lowered to $54 from $63 at Leerink |
| May 28, 2025 11:11 am | Greg Harrison | Scotiabank | $32.00 | $11.82 | TheFly | Arcturus Therapeutics initiated with an Outperform at Scotiabank |
| March 10, 2025 9:14 am | Thomas Shrader | BTIG | $48.00 | $14.55 | StreetInsider | BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT) |
| November 11, 2024 12:11 pm | Whitney Ijem | Canaccord Genuity | $10.58 | $3.02 | StreetInsider | Arcturus Therapeutics (ARCT) PT Raised to $74 at Canaccord Genuity |
| August 6, 2024 8:27 am | Whitney Ijem | Canaccord Genuity | $10.30 | $3.20 | TheFly | Arcturus Therapeutics price target lowered to $72 from $86 at Canaccord |
| July 2, 2024 6:38 am | Ed Arce | H.C. Wainwright | $8.58 | $3.38 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT) |
| May 31, 2024 7:40 am | Yasmeen Rahimi | Piper Sandler | $20.02 | $5.64 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Arcturus Therapeutics (ARCT) |
| May 10, 2024 7:24 am | Whitney Ijem | Canaccord Genuity | $12.30 | $3.83 | TheFly | Arcturus Therapeutics price target lowered to $86 from $87 at Canaccord |
| March 19, 2024 2:37 pm | Yale Jen | Laidlaw | $11.30 | $4.83 | StreetInsider | Laidlaw Reiterates Buy Rating on Arcturus Therapeutics (ARCT) |
Latest News for ARCT
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close…
Arcturus Therapeutics (NASDAQ: ARCT) used a presentation at Guggenheim's 2026 Emerging Outlook Biotech Summit to highlight upcoming milestones for its messenger RNA (mRNA) rare disease pipeline, with CEO Joe Payne emphasizing progress in inhaled mRNA for cystic fibrosis (CF) and an intravenously dosed liver-targeted program for ornithine transcarbamylase (OTC) deficiency. Positioning as an mRNA medicines company
Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary cash support. ARCT is priced as a busted biotech with optionality; cash runway extends to 2028, but clinical and regulatory risks remain significant. ARCT-032's 12-week trial and ARCT-810's FDA alignment are key re-rating catalysts; both programs face pivotal data and regulatory endpoints.
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARCT.
U.S. House Trading
No House trades found for ARCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.